<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705078</url>
  </required_header>
  <id_info>
    <org_study_id>N/2018/76</org_study_id>
    <nct_id>NCT03705078</nct_id>
  </id_info>
  <brief_title>&quot;Early TIPS&quot; Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices</brief_title>
  <acronym>GAVAPROSEC</acronym>
  <official_title>A Multicenter Randomized Clinical Trial Comparing Two Treatment Strategies to Prevent Rebleeding From Gastric Varices: &quot;Early TIPS&quot; Versus Glue Obliteration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate the superiority of an &quot;early tips&quot;
      strategy over standard treatment by glue obliteration (G0) in preventing bleeding recurrence
      or death at one year after a non GOV1 gastric variceal bleeding in cirrhotic patients
      initially treated by GO.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinically significant rebleeding (upper gastrointestinal bleeding whatever its origin)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined by Baveno VI consens group as a recurrent melena or hematemesis resulting in any of the following:
Hospital admission
Blood transfusion
3 g/dL drop in hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality and liver-related mortality</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality and liver-related mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rebleeding</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rebleeding</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rebleeding</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rebleeding</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of packed red blood cells</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of packed red blood cells</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications of cirrhosis (infections, ascites, hepatic encephalopathy, hepatorenal syndrome) during follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of TIPS complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of glue obliteration complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score (Model for End Stage Liver Disease) in TIPS group</measure>
    <time_frame>6 months</time_frame>
    <description>MELD score = 9.57*LN(creatinin in mg/dl) + 3.78*LN(Bilirubin in mg/dl) + 11.2*LN(INR) + 6.43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score (Model for End Stage Liver Disease) in glue obliteration group</measure>
    <time_frame>6 months</time_frame>
    <description>MELD score = 9.57*LN(creatinin in mg/dl) + 3.78*LN(Bilirubin in mg/dl) + 11.2*LN(INR) + 6.43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Bleeding Gastric Varices</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>early TIPS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transjugular portosytemic shunt within 72h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glue obliteration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>glue obliteration repeated sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transjugular Portosytemic Shunt (TIPS)</intervention_name>
    <description>The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.</description>
    <arm_group_label>early TIPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>glue obliteration</intervention_name>
    <description>The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.</description>
    <arm_group_label>Glue obliteration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhotic patients: the diagnosis of liver cirrhosis will be based on previous needle
             liver biopsy or on the combination of clinical, biochemical, and radiological
             findings. If biopsy findings are unavailable and in case of non-complicated cirrhosis,
             non-invasive markers will be used.

          -  Variceal bleeding at endoscopy from gastroesophageal gastric varices type 2 or
             isolated gastric varices type 1 or 2 (Sarin classification) according to the following
             criteria: endoscopic signs of an active spurting or oozing from gastric varices (GV);
             adherent blood clots, white nipple signs, or erosions on the GV and absence of other
             bleeding sources.

          -  Hemodynamically stable patient (systolic pressure above 90 mmHg) without clinical
             significant rebleeding (Baveno criteria) within 12 hours after the initial endoscopy
             with glue obliteration.

          -  Patients listed for liver transplantation can be included if the expected time on
             waiting list is up to 2 months.

          -  Written informed consent obtained.

        Exclusion Criteria:

          -  Pregnant woman or breastfeeding.

          -  Minor and patients older than 75 years.

          -  Non cirrhotic portal hypertension.

          -  Hepatocellular carcinoma outside the Milan criteria or other cancer at a palliative
             stage.

          -  Child Pugh score &gt; 13.

          -  History of severe or refractory hepatic encephalopathy unrelated to gastrointestinal
             bleeding.

          -  Congestive heart failure.

          -  History or presence of pulmonary hypertension.

          -  Patients with other indication for TIPS.

          -  Uncontrolled gastric variceal bleeding.

          -  Portal vein cavernoma.

          -  Patient who have previously received a TIPS procedure.

          -  Any extra hepatic clinical situation with a very poor short-term prognosis (for
             example multi-organ failure).

          -  Failure to receive clear information in patients without an identified trusted person.

          -  Refusal of the participation agreement by signing the information form and consent as
             defined.

          -  Exclusion period from another biomedical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Paul jpcervoni@chu-besancon.fr, Doctor</last_name>
    <phone>0033 381 668 020</phone>
    <email>jpcervoni@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphanie François, Master</last_name>
    <phone>0033 381 218 988</phone>
    <email>sfrancois@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric Oberti, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul Cervoni, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerity Hospital of Bondy</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland Amathieu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Henri Bernard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Ollivier, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Latournerie, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Louvet, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Borentain, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie Faure, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Archambeaud, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodolph Anty, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié Salpétrière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Thabut, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Carbonell, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Jezequel, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Bureau, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis D'Alteroche, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paul Brousse Hospital</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faouzi Saliba, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bleeding gastric varices</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>type 2 gastro-esophageal varices</keyword>
  <keyword>isolated gastric varices</keyword>
  <keyword>transjugular intra-hepatic porto systemic shunt (TIPS)</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>glue obliteration</keyword>
  <keyword>tissue adhesive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

